<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632407</url>
  </required_header>
  <id_info>
    <org_study_id>CT/2019/CANFLAX</org_study_id>
    <nct_id>NCT04632407</nct_id>
  </id_info>
  <brief_title>Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?</brief_title>
  <acronym>CANFLAX</acronym>
  <official_title>Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Boniface Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Boniface Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the current research program is to examine the use of nutraceuticals, in&#xD;
      particular flaxseed (FLX), in the prevention of Doxorubicin and Trastuzumab (DOX+TRZ)&#xD;
      mediated cardiotoxicity in the clinical setting. As Manitoba continues to be one of the top&#xD;
      FLX producers in the world, there is an increasing public awareness of the importance of the&#xD;
      consumption of this whole grain commodity in the prevention of cancer and cardiovascular&#xD;
      disease. In North America, approximately 1 in 8 women will develop breast cancer and will&#xD;
      receive treatment with DOX+TRZ. Although women with breast cancer are at risk of developing&#xD;
      heart failure due to chemotherapy, FLX has the capacity to prevent this outcome. The purpose&#xD;
      of the CANFLAX study is to establish FLX &quot;milk&quot; as an effective method in preventing heart&#xD;
      failure in women with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular toxicity is a potential short and long-term complication of anti-cancer&#xD;
      therapy with DOX+TRZ in the breast cancer setting. Although FLX is commonly consumed in up to&#xD;
      30% of women with breast cancer to improve overall disease burden and survival, it is&#xD;
      important to study whether this natural dietary agent can also reduce the cardiotoxic side&#xD;
      effects of DOX+TRZ in the clinical setting. The investigators hypothesize that the&#xD;
      prophylactic consumption of FLX &quot;milk&quot; will prevent adverse cardiovascular remodeling and&#xD;
      improve overall functional capacity in women with breast cancer receiving DOX+TRZ therapy.&#xD;
      The two specific aims of the CANFLAX study include: Aim 1: FLX &quot;milk&quot; will prevent the&#xD;
      development of heart failure in women with early stage breast cancer (EBC) who are treated&#xD;
      with DOX+TRZ based chemotherapy; and Aim 2: FLX &quot;milk&quot; will improve cardiac functional&#xD;
      capacity in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study participants will be randomized to either oat fibre &quot;milk&quot; or flax &quot;milk&quot;</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The 2 products (oat fibre &quot;milk&quot; and flax &quot;milk&quot;) are assigned a unique ID code.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) change</measure>
    <time_frame>1 year</time_frame>
    <description>Left ventricular ejection fraction (LVEF %) will be evaluated using transthoracic echocardiography at baseline and 12 month follow-up. A difference in LVEF&gt;10% from baseline will be considered significant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Flax &quot;milk&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 30 women will receive flax (FLX) &quot;milk&quot; on a daily basis for a total of 4 months. The FLX &quot;milk&quot; will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oat fibre &quot;milk&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 30 women will receive the oat fiber &quot;milk&quot; on a daily basis for a total of 4 months. The oat fibre &quot;milk&quot; will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flax &quot;milk&quot;</intervention_name>
    <description>See above</description>
    <arm_group_label>Flax &quot;milk&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oat fibre &quot;milk&quot;</intervention_name>
    <description>See above</description>
    <arm_group_label>Oat fibre &quot;milk&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  i) â‰¥18 years old;&#xD;
&#xD;
          -  ii) women with newly diagnosed early stage breast cancer (Stage I-IIIA)&#xD;
&#xD;
          -  iii) chemotherapy with 5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or&#xD;
             adriamycin and cyclophosphamide (AC) for 4 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  i) pre-existing diagnosis of heart failure and/or LVEF&lt;40%&#xD;
&#xD;
          -  ii) pre-existing use of anti-hypertensive agents including ACE inhibitors (ACEi) or&#xD;
             beta blockers&#xD;
&#xD;
          -  iii) planned use of any herbal/antioxidant/fatty acid/nutritional supplements at any&#xD;
             time in the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davinder S Jassal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davinder S Jassal, MD</last_name>
    <phone>2042372023</phone>
    <email>djassal@sbgh.mb.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Boniface Albrechtsen Research Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2E1J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davinder S Jassal, MD</last_name>
      <phone>2042372023</phone>
      <email>djassal@sbgh.mb.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Boniface Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Davinder S. Jassal</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cardiotoxicity</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Flaxseed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

